Altimmune, Inc. (ALT)
| Market Cap | 535.99M |
| Revenue (ttm) | 41,000 |
| Net Income (ttm) | -88.09M |
| Shares Out | 194.20M |
| EPS (ttm) | -1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,662,729 |
| Open | 2.780 |
| Previous Close | 2.800 |
| Day's Range | 2.750 - 2.850 |
| 52-Week Range | 2.750 - 7.730 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 17.67 (+540.22%) |
| Earnings Date | May 8, 2026 |
About ALT
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. [Read more]
Financial Performance
In 2025, Altimmune's revenue was $41,000, an increase of 105.00% compared to the previous year's $20,000. Losses were -$88.09 million, -7.33% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price target is $17.67, which is an increase of 540.22% from the latest price.
News
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
$225 million funded at closing, with an additional $225 million warrant tranche Financing funds operations through anticipated Phase 3 MASH 52-week data readout Financing was led by Deep Track Capital...
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune Announces Proposed Underwritten Public Offering of Securities
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune Transcript: AGM 2026
The meeting covered director elections, auditor ratification, executive compensation, and amendments to share authorization and employee stock plans. All proposals passed by majority or plurality vote, with results to be filed with the SEC.
Altimmune Transcript: Barclays 28th Annual Global Healthcare Conference
Phase II data for pemvidutide in MASH showed strong resolution and anti-fibrotic effects, supporting a differentiated phase III design with AI-assisted histology. Progress continues in AUD and ALD trials, with financial and leadership enhancements positioning for late-stage success.
Altimmune Transcript: Leerink Global Healthcare Conference 2026
Recent clinical data and regulatory milestones support advancing pemvidutide into phase III for MASH, with a focus on its unique dual agonism, strong tolerability, and potential for both monotherapy and combination use. Ongoing phase II trials in AUD and ALD may further expand its indications.
Altimmune Transcript: The Citizens Life Sciences Conference 2026
Pemvidutide is advancing toward a phase III trial in MASH, supported by strong phase II data on MASH resolution, weight loss, and tolerability. Its unique one-to-one glucagon/GLP-1 ratio and commercial strategy aim to address key unmet needs, with a solid financial runway into 2028.
Altimmune Earnings Call Transcript: Q4 2025
Pemvidutide advanced toward phase 3 for MASH with strong phase 2b efficacy, FDA Breakthrough Therapy designation, and robust financials supporting a global pivotal trial. Physician interest is high, and cash runway extends into 2028.
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) ...
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today anno...
Obesity stocks slump on Novo's underwhelming 2026 sales forecast
Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-...
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced ...
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
Altimmune Inc (NASDAQ: ALT) shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced ...
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA Alignment on Phase 3 registrational trial parameters confirmed fol...
Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide.
Altimmune Transcript: Study Result
IMPACT phase 2b 48-week data for pemvidutide in MASH showed significant, dose-dependent improvements in fibrosis markers, liver fat, and weight loss, with a strong safety and tolerability profile. Regulatory alignment with the FDA supports a phase 3 program using both 1.8 mg and 2.4 mg doses and innovative AI pathology tools.
Altimmune's drug for a type of liver disease shows benefits in mid-stage study
Altimmune said on Friday its experimental drug improved signs of liver scarring and liver health after 48 weeks of treatment in a mid-stage study of patients with a serious fatty liver disease known a...
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint
Altimmune Transcript: Piper Sandler 37th Annual Healthcare Conference
Leadership transition is underway as the company prepares for phase III trials and commercialization, with key regulatory and data milestones expected by year-end. Pemvidutide’s flexible trial design and strong early data support its potential in MASH, AUD, and ALD, while commercial capabilities are being built.
Altimmune Announces CEO Transition and Succession Plan
Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometa...
Altimmune Transcript: Jefferies London Healthcare Conference 2025
A dual GLP-1/glucagon agonist is advancing for MASH, AUD, and ALD, showing strong efficacy and tolerability in early trials. Phase three planning is underway, with flexibility for regulatory changes and a focus on both liver and metabolic benefits.
Altimmune Transcript: Stifel 2025 Healthcare Conference
Pemvidutide, a balanced glucagon/GLP-1 dual agonist, demonstrated rapid MASH resolution, strong anti-fibrotic activity, and quality weight loss in 24-week data, with 48-week results expected soon. The program is well-positioned for regulatory flexibility and expansion into AUD and ALD, supported by strong tolerability and financial resources.